Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19055
Title: Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Austin Authors: Bowyer, Samantha;Prithviraj, Prashanth;Lorigan, Paul;Larkin, James;McArthur, Grant;Atkinson, Victoria;Millward, Michael;Khou, Muoi;Diem, Stefan;Ramanujam, Sangeetha;Kong, Ben;Liniker, Elizabeth;Guminski, Alexander;Parente, Phillip;Andrews, Miles C;Parakh, Sagun ;Cebon, Jonathan S ;Long, Georgina V;Carlino, Matteo S;Klein, Oliver 
Affiliation: The Christie NHS Foundation Trust and University of Manchester, Manchester, UK
Royal Marsden Hospital NHS Foundation Trust, London, UK
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
University of Sydney, Sydney, New South Wales, Australia
Box Hill Hospital, Melbourne, Victoria, Australia
Princess Alexandra Hospital, Greenslopes Private Hospital, Brisbane, Queensland, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Melanoma Institute Australia, Sydney, New South Wales, Australia
Department of Medical Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
School of Medicine and Pharmacology, University of Western Australia, Australia, Nedlands, Western Australia, Australia
Rockingham General Hospital, Perth, Western Australia, Australia
Westmead Hospital, Sydney, New South Wales, Australia
Issue Date: 11-Apr-2017
metadata.dc.date: 2017-03-21
Publication information: British Journal of Cancer 2017; 116(8): e15
URI: http://ahro.austin.org.au/austinjspui/handle/1/19055
DOI: 10.1038/bjc.2017.59
PubMed URL: 28324885
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 7, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.